The Pharma Data

DECEMBER 17, 2020

COVID-19 vaccine developers are faced with an ethical quandary — whether to let phase 3 trial participants become “unblinded” and to receive authorized vaccines as they become available, which could hinder the collection of meaningful trial data. Pfizer, which has received emergency approvals in the U.S.

Vaccine 52

Vaccine Trials Long-Term Care Facilities FDA 52

The Pharma Data

DECEMBER 4, 2020

Having beat the United States to emergency authorization may pressure American regulators, who are already taking heat for not moving faster to get doses to people, the Times reported. Around the world, researchers are testing 57 vaccines in clinical trials, and nearly 100 others are being tested in animals or cell, the Times reported.

Long-Term Care Facilities 52

Long-Term Care Facilities Vaccine Nurses Hospitals 52

The Pharma Data

DECEMBER 3, 2020

Having beat the United States to emergency authorization may pressure American regulators, who are already taking heat for not moving faster to get doses to people, the Times reported. Around the world, researchers are testing 57 vaccines in clinical trials, and nearly 100 others are being tested in animals or cell, the Times reported.

Hospitals 52

Hospitals Long-Term Care Facilities Vaccine Nurses 52

The Pharma Data

DECEMBER 2, 2020

Having beat the United States to emergency approval of a coronavirus vaccine may pressure American regulators, who are already taking heat for not moving faster to get doses to people, The New York Times reported. The global race to develop a vaccine has been stunningly fast. Hospitalizations reach record high.

Vaccine 40

Vaccine Long-Term Care Facilities Hospitals Nurses 40

The Pharma Data

DECEMBER 21, 2020

A study published in the journal Cell Discovery back in March initially suggested that melatonin – and repurposing existing medicines in general – may be the key to regulating COVID-19 within the body. A study published as recently as November took a closer look at the theory.

Long-Term Care Facilities 52

Long-Term Care Facilities Vaccine Virus Clinical Trials 52

The Pharma Data

OCTOBER 28, 2020

Discussions with global regulators are ongoing. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing.

Government 40

Government Long-Term Care Facilities Hospitals Therapies 40

The Pharma Data

NOVEMBER 9, 2020

We thank those who have contributed to this medical advancement, particularly the clinical trial investigators and participants around the country.” Lilly is in discussions with global regulators to make bamlanivimab available around the world. Across all treatment arms, the trial will enroll over 800 participants.

Treatment 52

Treatment FDA Hospitals Long-Term Care Facilities 52